Pilot Study of Dietary Modification of Appetite Set Point in Obesity
NCT ID: NCT00726271
Last Updated: 2021-04-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
50 participants
INTERVENTIONAL
2008-06-30
2008-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Specific Aims
* To test the acceptance of, and the patients' compliance rate to, the Shangri-La Diet
* To ascertain whether a controlled clinical trial of the Shangri-La Diet would be feasible.
* To see if the weight loss documented anecdotally in many people is reproducible in patients from low-income areas who are overweight and taking prescribed medications associated with increased appetite and weight gain.
Analysis: The primary end point will be acceptability of the dietary intervention as measured by the final interview and the evaluation form-is this something patients would be willing to do over the long term? This will help determine whether a controlled trial of the dietary intervention would be feasible, and provide information needed to design such a trial. Secondary outcomes will be changes in the participants' weight, waist measurements, anxiety, and depression scores
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Paleo Diet 8wk Feasibility in Overweight Adults
NCT03814473
Factors Affecting Caloric Regulation in Human Feeding
NCT00108784
Does Meal Replacement With a Carbohydrates and Protein Supplement Induce Weight Loss in Overweight and/or Obese Adults?
NCT04458493
Impact of a Satiating Diet in Obese Men With a Low Satiety Phenotype
NCT03128697
A Novel Diet-Phenotype Interaction Affecting Body Weight
NCT01303757
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Specific Aims
* To test the acceptance of, and the patients' compliance rate to, the Shangri-La Diet
* To ascertain whether a controlled clinical trial of the Shangri-La Diet would be feasible.
* To see if the weight loss documented anecdotally in many people is reproducible in patients from low-income areas who are overweight and taking prescribed medications associated with increased appetite and weight gain.
Methods
2\. Subjects will receive light olive oil, and capsules of fish oil and flaxseed oil, to take daily at home with weight based dosing, based on the doses recommended in Dr. Roberts' work. Doses are within the recommended dietary ranges to improve intermediate outcomes for coronary artery disease (HDL, LDL, and triglycerides) and ranges associated with a decreased risk of cardiac and all cause mortality in epidemiological studies. They will return weekly for measurement of weight, waist measurements, discussion of any problems with the oils, and dose adjustment of the oils.
3\. Evaluation: At the end of 6 weeks of the intervention, the subjects will complete the same questionnaires as at baseline, and an evaluation form about the intervention.
Analysis: The primary end point will be acceptability of the dietary intervention as measured by the final interview and the evaluation form-is this something patients would be willing to do over the long term? Secondary outcomes will be changes in the participants' weight, waist measurements, anxiety, and depression scores.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
active
Subjects will complete the Zung Depression and Anxiety Scales. At the first visit the subject's medication list, weight, height, and waist measurement will be obtained. The goal is to recruit a minimum of 20 patients.
Subjects will receive light olive oil, and capsules of fish oil and flaxseed oil, to take daily at home with weight based dosing, based on the doses recommended in Dr. Roberts' work. Doses are within the recommended dietary ranges to improve intermediate outcomes for coronary artery disease subjects.
They will return weekly for measurement of weight, waist measurements, discussion of any problems with the oils, and dose adjustment of the oils.
light olive oil, fish oil capsules, flax seed oil capsules
fish oil 1000 mg capsules three daily flax seed oil 1000 mg capsules three daily light olive oil 30 ml to 60 ml daily(weight less than 160 pounds, 30 ml/ weight 160-200 pounds 45 ml/ weight over 200 pounds 60 ml)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
light olive oil, fish oil capsules, flax seed oil capsules
fish oil 1000 mg capsules three daily flax seed oil 1000 mg capsules three daily light olive oil 30 ml to 60 ml daily(weight less than 160 pounds, 30 ml/ weight 160-200 pounds 45 ml/ weight over 200 pounds 60 ml)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. BMI must be over 29
3. Must be fluent in English
4. Must have access to a telephone
5. Must be able and willing to come in for weekly measurements during the six weeks
6. Must not be known to be currently hypothyroid or hyperthyroid. Someone who is euthyroid on replacement could be eligible
Exclusion Criteria
2. Type 1 Diabetes
3. Inability to read at the 4th grade level
4. Current alcohol abuse as determined by the primary provider, or illicit substance use
5. Current warfarin use
6. Bleeding disorder or thrombocytopenia
7. Allergy to fish oil, flaxseed oil, or olive oil
8. Current use of any medication that has a probable negative interaction with any of the oils used in the intervention
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
State University of New York - Upstate Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
SUNY Upstate Medical University, Syracuse, NY 13210
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lisa Kaufmann, MD
Role: PRINCIPAL_INVESTIGATOR
State University of New York - Upstate Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
SUNY Upstate Medical University
Syracuse, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
5653
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.